Skip to main content
SpringerLink
Log in

Sublingual Versus Subcutaneous Immunotherapy for Allergic Rhinitis: What Are the Important Therapeutic and Real-World Considerations?

  • Immunotherapy and Immunomodulators (B Vickery, Section Editor)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Allergen immunotherapy has been used for over 100 years in the treatment of allergic rhinitis. With two major options for administering this disease-modifying therapy, SCIT, and SLIT, what is our current understanding of the efficacy and safety of each one? How do we determine who is the appropriate candidate for each one in the real world?

Recent Findings

SCIT and SLIT show significant improvement in clinical symptoms and need for medication in the treatment of allergic rhinitis. In recent meta-analyses, there is no significant difference in the efficacy between the two treatments, but SLIT has more local side effects though less systemic ones. Shared decision-making should be instituted to determine which treatment should be started in a patient with allergic rhinitis.

Summary

This review provides up-to-date information on the efficacy and safety of SCIT vs SLIT in the care of children and adults with allergic rhinitis in the real world and the role of shared decision-making in the use of these modalities.

Trial Registrations

Clinicaltrials.gov: NCT04145219 and NCT02478398

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:•• Of major importance

  1. Cohen SG, Richard E 3rd. Allergen immunotherapy in historical perspective. Clin Allergy Immunol. 2008;21:1–29.

    PubMed  Google Scholar 

  2. Fitzhugh DJ, Lockey RF. Allergen immunotherapy: a history of the first 100 years. Curr Opin Allergy Clin Immunol. 2011;11(6):554–9. https://doi.org/10.1097/ACI.0b013e32834c3134.

    Article  CAS  PubMed  Google Scholar 

  3. Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet. 1954;266(6821):1055–7. https://doi.org/10.1016/s0140-6736(54)91620-7.

    Article  CAS  PubMed  Google Scholar 

  4. Durham SR, Nelson H. Allergen immunotherapy: a centenary celebration. World Allergy Organ J. 2011;4(6):104–6. https://doi.org/10.1097/WOX.0b013e3182218920.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Passalacqua G, Bagnasco D, Canonica GW. 30 years of sublingual immunotherapy. Allergy. 2019. https://doi.org/10.1111/all.14113.

  6. •• Globinska A, Boonpiyathad T, Satitsuksanoa P, Kleuskens M, van de Veen W, Sokolowska M, et al. Mechanisms of allergen-specific immunotherapy: diverse mechanisms of immune tolerance to allergens. Ann Allergy Asthma Immunol. 2018;121(3):306–12. https://doi.org/10.1016/j.anai.2018.06.026This update gives an excellent review of the diverse mechanisms of allergen immunotherapy and provides an insight into alternative routes of administration.

    Article  CAS  PubMed  Google Scholar 

  7. Palomares O, Akdis M, Martin-Fontecha M, Akdis CA. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. Immunol Rev. 2017;278(1):219–36. https://doi.org/10.1111/imr.12555.

    Article  CAS  PubMed  Google Scholar 

  8. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007(1):Cd001936. https://doi.org/10.1002/14651858.CD001936.pub2.

  9. Rondon C, Blanca-Lopez N, Campo P, Mayorga C, Jurado-Escobar R, Torres MJ, et al. Specific immunotherapy in local allergic rhinitis: a randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Allergy. 2018;73(4):905–15. https://doi.org/10.1111/all.13350.

    Article  CAS  PubMed  Google Scholar 

  10. Huang Y, Wang C, Cao F, Zhao Y, Lou H, Zhang L. Comparison of Long-term efficacy of subcutaneous immunotherapy in pediatric and adult patients with allergic rhinitis. Allergy, Asthma Immunol Res. 2019;11(1):68–78. https://doi.org/10.4168/aair.2019.11.1.68.

    Article  CAS  Google Scholar 

  11. Song Y, Long J, Wang T, Xie J, Wang M, Tan G. Long-term efficacy of standardised specific subcutaneous immunotherapy in children with persistent allergic rhinitis due to multiple allergens including house dust mites. J Laryngol Otol. 2018;132(3):230–5. https://doi.org/10.1017/s0022215117002547.

    Article  CAS  PubMed  Google Scholar 

  12. Huang Y, Wang C, Wang X, Zhang L, Lou H. Efficacy and safety of subcutaneous immunotherapy with house dust mite for allergic rhinitis: a meta-analysis of randomized controlled trials. Allergy. 2019;74(1):189–92. https://doi.org/10.1111/all.13583.

    Article  PubMed  Google Scholar 

  13. Mustafa SS, Bingemann T, Blue H, Conn K, Hanley T, Ramsey A. Systemic reactions to subcutaneous immunotherapy: effects of dosing and aeroallergen content. Ann Allergy Asthma Immunol. 2019;123(3):284–7. https://doi.org/10.1016/j.anai.2019.06.021.

    Article  CAS  PubMed  Google Scholar 

  14. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008–2013). Ann Allergy Asthma Immunol. 2016;116(4):354–9.e2. https://doi.org/10.1016/j.anai.2016.02.001.

    Article  PubMed  Google Scholar 

  15. Pfaar O, Lou H, Zhang Y, Klimek L, Zhang L. Recent developments and highlights in allergen immunotherapy. Allergy. 2018;73(12):2274–89. https://doi.org/10.1111/all.13652.

    Article  PubMed  Google Scholar 

  16. Epstein TG, Liss GM, Berendts KM, Bernstein DI. AAAAI/ACAAI Subcutaneous immunotherapy surveillance study (2013–2017): Fatalities, infections, delayed reactions, and use of epinephrine autoinjectors. J Allergy Clin Immunol Pract. 2019;7(6):1996–2003.e1. https://doi.org/10.1016/j.jaip.2019.01.058.

    Article  PubMed  Google Scholar 

  17. Cox LS. Sublingual immunotherapy: historical perspective and practical guidance. J Allergy Clin Immunol Pract. 2017;5(1):63–5. https://doi.org/10.1016/j.jaip.2016.11.016.

    Article  PubMed  Google Scholar 

  18. Tankersley M, Han JK, Nolte H. Clinical aspects of sublingual immunotherapy tablets and drops. Ann Allergy Asthma Immunol. 2020. https://doi.org/10.1016/j.anai.2019.12.025.

  19. Tucker MH, Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol. 2008;101(4):419–25. https://doi.org/10.1016/s1081-1206(10)60320-1.

    Article  PubMed  Google Scholar 

  20. •• Sivam A, Tankersley M. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey. Ann Allergy Asthma Immunol. 2019;122(6):623–9.e2. https://doi.org/10.1016/j.anai.2019.03.023This survey shows the uptake by Board-Certified allergists in using SLIT with FDA approved products and barriers for increased use.

    Article  PubMed  Google Scholar 

  21. Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol. 2012;130(1):215–24.e7. https://doi.org/10.1016/j.jaci.2012.04.021.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Creticos PS, Esch RE, Couroux P, Gentile D, D'Angelo P, Whitlow B, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014;133(3):751–8. https://doi.org/10.1016/j.jaci.2013.10.041.

    Article  CAS  PubMed  Google Scholar 

  23. Mosges R, Breitruck NY, Allekotte S, Shah-Hosseini K, Dao VA, Zieglmayer P, et al. Shortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season. World Allergy Organ J. 2019;12(2):100012. https://doi.org/10.1016/j.waojou.2019.100012.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011;127(1):72–80, .e1-2. https://doi.org/10.1016/j.jaci.2010.11.035.

    Article  CAS  PubMed  Google Scholar 

  25. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in north American children and adolescents. J Allergy Clin Immunol. 2011;127(1):64–71, .e1-4. https://doi.org/10.1016/j.jaci.2010.11.034.

    Article  CAS  PubMed  Google Scholar 

  26. Maloney J, Bernstein DI, Nelson H, Creticos P, Hebert J, Noonan M, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):146–53.e2. https://doi.org/10.1016/j.anai.2013.11.018.

    Article  CAS  PubMed  Google Scholar 

  27. Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016;138(6):1631–8. https://doi.org/10.1016/j.jaci.2016.06.044.

    Article  PubMed  Google Scholar 

  28. Masuyama K, Okamoto Y, Okamiya K, Azuma R, Fujinami T, Riis B, et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Allergy. 2018;73(12):2352–63. https://doi.org/10.1111/all.13544.

    Article  CAS  PubMed  Google Scholar 

  29. Okamoto Y, Fujieda S, Okano M, Hida H, Kakudo S, Masuyama K. Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: a randomized trial in a pediatric population. Pediatr Allergy Immunol. 2019;30(1):66–73. https://doi.org/10.1111/pai.12984.

    Article  PubMed  Google Scholar 

  30. Didier A, Malling HJ, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5:12. https://doi.org/10.1186/s13601-015-0057-8.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–25.e5. https://doi.org/10.1016/j.jaci.2011.12.973.

    Article  PubMed  Google Scholar 

  32. Nolte H, Maloney J. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. Allergol Int. 2018;67(3):301–8. https://doi.org/10.1016/j.alit.2018.03.008.

    Article  CAS  PubMed  Google Scholar 

  33. Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sorensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529–38.e13. https://doi.org/10.1016/j.jaci.2017.06.014.

    Article  CAS  PubMed  Google Scholar 

  34. Halken S, Roberts G, Valovirta E, Nolte H, Hulstrom V, Blaiss MS. Safety of timothy grass sublingual immunotherapy tablet in children: pooled analyses of clinical trials. J Allergy Clin Immunol Pract. 2020;8:1387–1393.e2. https://doi.org/10.1016/j.jaip.2020.01.008.

    Article  PubMed  Google Scholar 

  35. •• James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017;17(1):55–9. https://doi.org/10.1097/aci.0000000000000335Excellent review discussing safety of allergen immunotherapy emphasizing low risk of anaphylaxis with SCIT and local reactions due to SLIT.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Tang LX, Yang XJ, Wang PP, Ge WT, Zhang J, Guo YL, et al. Efficacy and safety of sublingual immunotherapy with Dermatophagoides farinae drops in pre-school and school-age children with allergic rhinitis. Allergol Immunopathol (Madr). 2018;46(2):107–11. https://doi.org/10.1016/j.aller.2017.09.022.

    Article  Google Scholar 

  37. Zhang YZ, Luo J, Wang ZH, Wang J. Efficacy and safety of sublingual dust mite drops in children with mono- or polysensitized allergic rhinitis. Am J Otolaryngol. 2019;40(5):755–60. https://doi.org/10.1016/j.amjoto.2019.07.010.

    Article  CAS  PubMed  Google Scholar 

  38. Zhong C, Yang W, Li Y, Zou L, Deng Z, Liu M, et al. Clinical evaluation for sublingual immunotherapy with Dermatophagoides farinae drops in adult patients with allergic asthma. Ir J Med Sci. 2018;187(2):441–6. https://doi.org/10.1007/s11845-017-1685-x.

    Article  CAS  PubMed  Google Scholar 

  39. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;(12):Cd002893. https://doi.org/10.1002/14651858.Cd002893.

  40. Epstein TG, Calabria C, Cox LS, Dreborg S. Current evidence on safety and practical considerations for administration of sublingual allergen immunotherapy (SLIT) in the United States. J Allergy Clin Immunol Pract. 2017;5(1):34–40.e2. https://doi.org/10.1016/j.jaip.2016.09.017.

    Article  PubMed  Google Scholar 

  41. Casale TB, Canonica GW, Bousquet J, Cox L, Lockey R, Nelson HS, et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol. 2009;124(4):665–70. https://doi.org/10.1016/j.jaci.2009.07.054.

    Article  PubMed  Google Scholar 

  42. Bernstein DI, Bardelas JA Jr, Svanholm Fogh B, Kaur A, Li Z, Nolte H. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice. Postgrad Med. 2017;129(6):590–7. https://doi.org/10.1080/00325481.2017.1302306.

    Article  PubMed  Google Scholar 

  43. •• Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017;72(11):1597–631. https://doi.org/10.1111/all.13201A definitive review and meta-analysis by the European Academy of Allergy and Clinical Immunology showing efficacy of allergen immunotherapy while on treatment and data suggesting sustained effect on discontinuation of therapy.

    Article  CAS  PubMed  Google Scholar 

  44. Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28(1):18–29. https://doi.org/10.1111/pai.12661.

    Article  PubMed  Google Scholar 

  45. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Macchia L, Di Lorenzo G. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy. 2017;72(5):691–704. https://doi.org/10.1111/all.13104.

    Article  PubMed  Google Scholar 

  46. Chaaban MR, Mansi A, Tripple JW, Wise SK. SCIT Versus SLIT: which one do you recommend, doc? Am J Med Sci. 2019;357(5):442–7. https://doi.org/10.1016/j.amjms.2019.02.004.

    Article  PubMed  Google Scholar 

  47. Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract. 2014;2(2):144–9; quiz 50-1. https://doi.org/10.1016/j.jaip.2013.11.018.

    Article  PubMed  Google Scholar 

  48. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol. 2016;137(2):339–49.e10. https://doi.org/10.1016/j.jaci.2015.12.1298.

    Article  PubMed  Google Scholar 

  49. Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy. 1996;26(11):1253–61.

    Article  CAS  Google Scholar 

  50. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004;59(1):45–53. https://doi.org/10.1046/j.1398-9995.2003.00387.x.

    Article  CAS  PubMed  Google Scholar 

  51. Ventura MT, Carretta A, Tummolo RA, Buquicchio R, Arsieni A, Murgia N. Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy. Int J Immunopathol Pharmacol. 2009;22(2):403–13. https://doi.org/10.1177/039463200902200217.

    Article  CAS  PubMed  Google Scholar 

  52. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol. 2012;157(3):288–98. https://doi.org/10.1159/000327566.

    Article  CAS  PubMed  Google Scholar 

  53. •• Blaiss MS, Steven GC, Bender B, Bukstein DA, Meltzer EO, Winders T. Shared decision making for the allergist. Ann Allergy Asthma Immunol. 2019;122(5):463–70. https://doi.org/10.1016/j.anai.2018.08.019An excellent review on how shared decision making works and provide practical advice and allergist-specific shared decision making resources.

    Article  PubMed  Google Scholar 

  54. American Academy of Allergy Asthma and Immunology. Should I treat my allergies with immunotherapy? 2020. http://allergyrelief.acaai.org/. Accessed 1 Apr 2020.

  55. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016;137(2):358–68. https://doi.org/10.1016/j.jaci.2015.12.1300.

    Article  PubMed  Google Scholar 

  56. Wang T, Li Y, Wang F, Zhou C. Nonadherence to sublingual immunotherapy in allergic rhinitis: a real-life analysis. Int Forum Allergy Rhinol. 2017;7(4):389–92. https://doi.org/10.1002/alr.21909.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical College of Georgia at Augusta University, Augusta, GA, USA

    Kelsey Field & Michael S. Blaiss

  2. Roswell, GA, USA

    Michael S. Blaiss

Authors
  1. Kelsey Field
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael S. Blaiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael S. Blaiss.

Ethics declarations

Conflict of Interest

Michael S. Blaiss, MD, has received honorarium for consulting for ALK and Stallergenes/Greer. No other authors have any conflict of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Immunotherapy and Immunomodulators

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Field, K., Blaiss, M.S. Sublingual Versus Subcutaneous Immunotherapy for Allergic Rhinitis: What Are the Important Therapeutic and Real-World Considerations?. Curr Allergy Asthma Rep 20, 45 (2020). https://doi.org/10.1007/s11882-020-00934-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-020-00934-4

Keywords

Search

Navigation